Member Info for Bfdinvestor

The Chairman is a massive shareholder, so has far more to gain than any of us! Ageism is also plain wrong.

Where are you getting £3m from. The last placing was for £0.5m.

If there is any further placing, and it remains an if, it would be for a considerably smaller amount than £0.5m

Yes the Shein pandora's box of problems is starting to open up.

Shein.co.uk had a shocking month for website results in November where as BOO (and particularly Debenhams) was way ahead. Hopefully the start of better times

It seems to me that the only benefit of this supposed game is to use it as the basis of a filter list for the uninvested trolls.

That's what i've done anyway, the board is far better

Moon why not post the photos.

The RNS states that the build is almost complete, are you saying the RNS is a lie.

If so you should back it up because you are libelling the company if not

I'd agree with Lloyd, problems with the innovations pathway.

However, I can't see any news on that until next year Sprout

As I posted last night, if results follow the pattern of the previous two years they will be on Tuesday.

Really glad they didn't land today!

The key focus is on outlook imho, not half one financials which only go up to the end of September

There is probably very little cash, but conversely there is probably very little expenditure required in the next few months

It depends how quickly the mill is up and running, it it happens quickly there may not be a requirement for a placing.

It's impossible to be certain at the moment

Wolfy buys or sells of that size are done usually off book precisely to avoid affecting the retail price.

It could be either , I maintain my view.

For the last two years the interims have come out on the Tuesday of the last trading week before Christmas, can't see why this year would be different.

Definitely don't want results on a Friday as that is the day for releasing bad news, which I'm not expecting

Why do you think it's a sell.

It's actually closer in price to the buy at 12.47.

I've seen many times, as I posted the other day, that manufactured drops like we saw the other day are often to fill big orders.

That is the most likely scenario to me.

But I guess it depends if your glass is half empty or half full

I guess it's a case of glass half empty ornha

Somebody thinks so.

Look at the massive late reported buy.

Somebody wants in cheap.

Andrew Bailey has said much the same thing today, as has the ECB

No guarantee it will lead to a sustained AIM rally but it is long overdue.

Even after this rise, Boo is still valued at just over 3 months revenue. Other than ASOS I don't know of any other viable business with such a low valuation

Why is it a red herring.

One of the key take outs from yesterday is that treatment cycles are already being massively extended, leading to a better quality of life for far longer.

That is largely only happening because we haven't found MTD imho.

A massive sea of blue yet the sp goes marginally down.

We are still well below the price at the manufacturer drop a couple of days ago.

So much good news to come in hopefully short order now

Call me suspicious but look at the spread!

The news from the States and our GDP figures yesterday makes it likely interest rate drops will start from May /June next year. Real income in the UK is forecast to go up next year

Both of which mean that there is a bigger opportunity for AiM in general and Boo in particular.

Looking at November website visits, it would appear that Boo is gaining momentum again.

All of which looks good for investors and bad for shorters.

I'd like to see a sustained rise into the 40s to gain further confidence but I'm certainly happy to hold at the moment

Thx for your link

I'm still not sure what part of the objective they didn't answer yesterday

Perhaps you could explain.

And also expand on any of my points that you disagree with?

Brilliant news bring on the licence and the DFS and let's get digging

Cheers MrPinchy, me too

Rorkesdrift I'm confused.

The purpose of this trial was to ascertain safety and tolerability. So that is what today's presentation should have focussed on.

In my opinion that is exactly what it did.

My only criticism is that it could have honed in more on the key takeouts. So here is my view of what they are.

1. It works in the real world exactly as predicted from lab results. Dox is only cleaved in the tumour environment

2. In fact it works so well that they haven't been able to ascertain a maximum tolerated dose yet.

3. It works so well that they are able to continue treatment far beyond normal dox giving patients healthier and longer lives.

4. It works so well that it may even cure cancer in some patients where other options have failed.

5. It works so well that it will now be used as a first line treatment for some patients.

What else would you like a presentation focussed on a P1 trial to tell you

The issue is some people on here, which I warned against yesterday, tried to turn today into something it never was meant to be.

Because their dumb expectations haven't been met that is somehow the company's fault.

Now I believe Avacta require a good marketing/commercial director, I'm exceptionally frustrated by the sp action today, but that doesn't take away from my admiration for the results that were communicated today